Photos: https://drive.google.com/drive/folders/1OIKkIC7kIPhFq-FWR7pO1-JbERqg29mN?usp=sharing HONG KONG, July 16, 2025 -- With shells drawing near and only minutes to escape, what would you save? "I was forced to leave everything behind – my toys, my clothes, all the things I loved," said 8-year-old Syrian girl Amal. In the harsh winter of 2024, she and her family walked for two days to flee the conflict, carrying nothing but the thin clothes on their backs. Food, water, shelter, and even a sense of security were all unwillingly left behind. A Tent for a Home
KUALA LUMPUR, Malaysia, July 16, 2025 -- A regional effort to improve cervical cancer care for patients has launched in Malaysia. Involving 6 countries in Southeast Asia, Project ACTIVE 2.0 aims to enhance cervical cancer treatment and support patient recovery across Southeast Asia. The three-year initiative will focus on strengthening healthcare systems through clinical training, infrastructure upgrades, and digital innovations, with the goal of expanding access to high-quality, targeted cervical cancer care for patients and their families. Cervical cancer remains a significan
Study shows sustained improvements in heart failure symptoms and function following long-term C-MIC therapy ZUG, Switzerland, July 16, 2025 -- Berlin Heals, a pioneer in bioelectric medicine for the treatment of heart failure, is pleased to announce the publication of a new peer-reviewed study titled "Two-year outcomes of a cardiac microcurrent device in chronic heart failure: A first-in-human pilot study" in the ESC Heart Failure journal. The study presents the long-term follow-up of patients enrolled in the initial pilot trial of the Cardiac Microcurrent I
[ 메디채널 김갑성 기자 ] - AI Medical Service Inc. from Japan Wins Gold Prize - TOKYO, July 16, 2025 -- During the "Health and Well-being" theme week at the Expo 2025 Osaka, Kansai, the Japan External Trade Organization (JETRO) and Japan's Ministry of Economy, Trade and Industry (METI) jointly hosted an international symposium on healthcare and a pitch competition for healthcare startups from around the world, titled the "Global Healthcare Challenge" (GHeC), at the Grand Prince Hotel Osaka Bay on June 25 (Wednesday) and 26 (Thursday), 2025. The event was designed to help J
TAIPEI and SAN DIEGO, July 16, 2025 -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that its new drug Pidnarulex (CX-5461) has been selected by the U.S. National Cancer Institute (NCI) as part of a five-year cancer research program. The first patient in the monotherapy clinical trial for advanced solid tumors has been successfully enrolled at the NIH Clinical Center in Bethesda, Maryland, USA. The NCI will fund the full cost of the
MANILA, Philippines, July 16, 2025 -- Medley (TSE: 4480), a leading Japan-based healthcare technology group, has announced the relocation and expansion of its operational functions in the Philippines to help accelerate the company's global business growth. The new office, located at 32nd Street corner 3rd Avenue, Bonifacio Global City (BGC), Taguig City, offers a sleek, modern space for the company's fast-growing team. It will serve as a key operational hub for Medley's global business and underscores the company's continued commitment to international expansion. Remaining in
TOKYO, July 16, 2025 -- Fujitsu Limited and Acer Medical Inc., a provider of AI-powered medical imaging and preventative medicine, today announced a collaborative agreement to develop "aiGait" powered by Uvance, a solution that leverages Fujitsu's advanced skeleton recognition AI technology to detect gait pattern abnormalities, and provide gait quantization to healthcare professionals to support the early diagnosis of dementia and Parkinson's disease. The technology is part of "Fujitsu Kozuchi for Vision" from the Fujitsu Uvance offering "AI Technologies and Solutions
HONG KONG, July 16, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully enrolled in the registration Phase III clinical trial (AK112-312/HARMONi-GI6) of ivonescimab in first-line treatment for advanced metastatic colorectal cancer (mCRC). This randomized, controlled, multi-center Phase III clinical trial for first-line treatment of mCRC is one of the company's key initiatives to address the significant unmet clinical need worldwide with ivonescimab. Colorectal cancer remains the third mo
SHANGHAI, July 16, 2025 -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for Paediatric formulations (GAP-f), the World Health Organization (WHO) host network, ziresovir (10mg) has been included in the PADO-RSV priority list. Ziresovir, developed by Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), is the first and only RSV antiviral drug to be included in the list. This is the first time WHO has included an anti-RSV drug developed from China in the paediatric drug optimizati
FebriDx® is a first-in-class rapid test that differentiates between bacterial and non-bacterial respiratory infections, offering significant potential to address critical unmet needs in patient care by enabling more informed antibiotic use and aiding in the reduction of antimicrobial resistance. Introduction of FebriDx will enhance PHASE Scientific's INDICAID® portfolio and strengthen its leadership in point-of-care respiratory diagnostics. Partnership underscores PHASE Scientific's proven commercial execution in the U.S. market with its extensive nationwide clinical net